ClinicalTrials.gg
CompletedNCT02876172Updated Jun 4, 2025Results posted

MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

A Phase 1/2 interventional study of MDMA and CBCT in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
27th of 38
12 · median 25
Started
2016
the only one that year
Phase 1/2
2 of 38
none open now
Registered
9th of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 27th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 1/2, and was the 9th registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if cognitive-behavioral conjoint therapy (CBCT) in combination with MDMA-assisted therapy is safe and effective in people with chronic PTSD and their partners.

The main question it aims to answer is: Does MDMA-assisted CBCT reduce PTSD symptoms in people with chronic PTSD?

Participants (chronic PTSD patients and their partners) will undergo three non-drug preparatory therapy sessions, followed by two MDMA-assisted therapy sessions. Each MDMA-assisted therapy session will be followed by five non-drug integrative therapy using CBCT.

Read the detailed description

Cognitive-Behavioral Conjoint Therapy (CBCT) for PTSD is a three-phase, 15-session, manualized treatment. This Phase 1/2 open-label study will combine methods for conducting MDMA-assisted therapy with methods from the CBCT for PTSD in order to treat 10 participants with chronic PTSD and their partners (intimate or non-intimate significant other who does not have a current diagnosis of PTSD) in order to explore whether combined treatment is effective.

Each therapy team will have one therapist trained and experienced in MDMA-assisted therapy and one therapist trained and experienced in CBCT. During the first experimental session, both participants will receive 75 mg of midomafetamine HCl followed 1.5 to 2 hours later by an optional supplemental half-dose of 37.5 mg. During the second experimental session, an initial dose of either 100 or 75 mg of midomafetamine HCl will be administered to both participants followed by an optional supplemental half-dose of either 50 mg or 37.5 mg. The primary objective of this study is to assess changes in PTSD symptoms from Baseline to Primary Endpoint in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity scores in PTSD participants.

03

Conditions studied

  • Posttraumatic Stress Disorder

Keywords

  • PTSD
  • therapy
  • MDMA
  • dyad
  • cognitive behavioral therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All inclusion criteria for the PTSD and Concerned Significant Other (CSO) are identical except for first two items, marked below:
  • PTSD+ participant: Meet criteria for current PTSD and satisfies PTSD criteria via CAPS
  • CSO participant: Meet criteria for V62.89 Other Problem Related to Psychosocial Circumstances under Diagnostic and Statistical Manual 5 (DSM-5), as determined through clinical interview, for current psychosocial circumstances contributing to relationship distress with intimate or non-intimate partner
  • Are at least 18 years old
  • If in psychotherapy, willing and able to maintain that schedule without changing it
  • Are willing to refrain from taking any psychiatric medications during the study period, with the exception of gabapentin when prescribed for pain control.
  • Willing to remain overnight at the study site
  • Are willing to be driven home the morning after the experimental sessions, after the integrative therapy session
  • Are willing to commit to medication dosing, experimental sessions, follow-up sessions, to complete evaluation instruments and commit to be contacted for all necessary telephone contacts
  • Are willing to remain overnight at the study site after each experimental session until after the integrative session occurring the next morning
  • Must have a negative pregnancy test at study entry and prior to each experimental session if able to bear children, and must agree to use adequate through 10 days after the last dose of MDMA.
  • Must provide a contact (relative, spouse, close friend or other caregiver other than the CSO participant) who is willing and able to be reached by the Clinical Investigators in the event of a participant becoming suicidal.
  • Must agree to inform the Clinical Investigators within 48 hours of any medical conditions and procedures
  • Are proficient in speaking and reading English
  • Agree to have all clinic visit and Integrative Sessions recorded to audio and video
  • Agree to not participate in any other interventional clinical trials during the duration of this study

Exclusion criteria

Exclusion Criteria:

  • The following exclusions are identical for PTSD+ and CSO participants except for the following, marked below:
  • CSO participant only: Have diagnosis of current PTSD not in remission
  • Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of
  • Have evidence or history of significant medical disorders
  • Have hypertension
  • Have liver disease; asymptomatic participants with who have previously undergone evaluation and successful treatment is permitted.
  • History of hyponatremia or hyperthermia
  • Weigh less than 48 kg
  • Have used "Ecstasy" (material represented as containing MDMA) more than 10 times within the last 10 years or at least once within 6 months of the MDMA-assisted session
  • Are not able to give adequate
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    MDMA-assisted therapy and CBCT

    Cognitive-behavioral conjoint therapy and 2 sessions of MDMA-assisted therapy.

    Drug: MDMA · Behavioral: CBCT · Behavioral: Therapy

Interventions

  • DrugMDMA

    Two sessions of MDMA-assisted therapy, one with an initial dose of 75 mg midomafetamine HCl (and optional supplemental dose of 37.5 mg) and the second with 75 or 100 mg midomafetamine HCl (with optional supplemental dose of either 37.5 mg or 50 mg respectively) given to the participant with PTSD and their significant other.

    Also known as: 3,4-Methylenedioxymethamphetamine, midomafetamine

  • BehavioralCBCT

    A three-phase, 15-session, manualized treatment from the CBCT manual

    Also known as: Cognitive behavioral conjoint therapy

  • BehavioralTherapy

    Manualized MDMA-assisted therapy

06

What researchers measure

Primary outcomes

  1. Primary Endpoint Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score

    The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a CAPS-5 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Primary Endpoint (Visit 16, approximately 2 months later)

  2. Change From Baseline to Primary Endpoint CAPS-5 Total Severity Score

    The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a CAPS-5 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to Primary Endpoint (Visit 16, approximately 2 months later)

Secondary outcomes

  1. Baseline Pittsburgh Sleep Quality Index (PSQI)

    Self-reported questionnaire that assesses sleep quality and disturbances. The index looks at subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The component scores yield a total score which ranges 0-21 with a higher score indicating worse sleep quality.

    Time frame: Baseline (screening)

  2. Primary Endpoint Pittsburgh Sleep Quality Index (PSQI)

    Self-reported questionnaire that assesses sleep quality and disturbances. The index looks at subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The component scores yield a total score which ranges 0-21 with a higher score indicating worse sleep quality.

    Time frame: Primary Endpoint (Visit 16, approximately 2 months later)

  3. Baseline Patient Beck Depression Inventory-II (BDI-II)

    BDI-II is a 21-item self reported instrument used to measure severity of depressive symptoms. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.

    Time frame: Baseline (screening)

  4. Primary Endpoint Patient Beck Depression Inventory-II (BDI-II)

    BDI-II is a 21-item self reported instrument used to measure severity of depressive symptoms. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.

    Time frame: Primary Endpoint (Visit 16, approximately 2 months later)

  5. Baseline Patient Couples Satisfaction Index (CSI)

    The Couples Satisfaction Index (CSI) is a self-reported 32-item scale measuring one's satisfaction in a relationship. Questions discuss overall happiness in relationship, extent of agreement/ disagreement between partners, and feelings towards relationships and are scored on a likert scale from 0 to 5, with higher scores indicating higher satisfaction in the relationship. Scores range from 0 to 160.

    Time frame: Baseline (screening)

  6. Primary Endpoint Patient Couples Satisfaction Index (CSI)

    The Couples Satisfaction Index (CSI) is a self-reported 32-item scale measuring one's satisfaction in a relationship. Questions discuss overall happiness in relationship, extent of agreement/ disagreement between partners, and feelings towards relationships and are scored on a likert scale from 0 to 5, with higher scores indicating higher satisfaction in the relationship. Scores range from 0 to 160.

    Time frame: Primary Endpoint (Visit 16, approximately 2 months later)

  7. Baseline Partner Couples Satisfaction Index (CSI)

    The Couples Satisfaction Index (CSI) is a self-reported 32-item scale measuring one's satisfaction in a relationship. Questions discuss overall happiness in relationship, extent of agreement/ disagreement between partners, and feelings towards relationships and are scored on a likert scale from 0 to 5, with higher scores indicating higher satisfaction in the relationship. Scores range from 0 to 160.

    Time frame: Baseline (screening)

  8. Primary Endpoint Partner Couples Satisfaction Index (CSI)

    The Couples Satisfaction Index (CSI) is a self-reported 32-item scale measuring one's satisfaction in a relationship. Questions discuss overall happiness in relationship, extent of agreement/ disagreement between partners, and feelings towards relationships and are scored on a likert scale from 0 to 5, with higher scores indicating higher satisfaction in the relationship. Scores range from 0 to 160.

    Time frame: Primary Endpoint (Visit 16, approximately 2 months later)

  9. Baseline Trauma and Attachment Beliefs Scale (TABS)

    TABS is a 84-item self-report scale, which measures responses on a 1 to 6 scale (1 = "Disagree Strongly, 6 = Agree Strongly) the degree to which respondents believe the statements correspond with their own beliefs. The measures of these beliefs relate to self-safety, other-safety, self-trust, other-trust, self-esteem, other-esteem, self-intimacy, other-intimacy, self-control, and other control. A TABS total score is calculated by summing all of the items (range 84 to 504). Higher scores indicate greater disruption.

    Time frame: Baseline (screening)

  10. Primary Endpoint Trauma and Attachment Beliefs Scale (TABS)

    TABS is a 84-item self-report scale, which measures responses on a 1 to 6 scale (1 = "Disagree Strongly, 6 = Agree Strongly) the degree to which respondents believe the statements correspond with their own beliefs. The measures of these beliefs relate to self-safety, other-safety, self-trust, other-trust, self-esteem, other-esteem, self-intimacy, other-intimacy, self-control, and other control. A TABS total score is calculated by summing all of the items (range 84 to 504). Higher scores indicate greater disruption.

    Time frame: Primary Endpoint (Visit 16, approximately 2 months later)

  11. Baseline Emotion Regulation Questionnaire (ERQ) Reappraisal Subscale

    ERQ measures self-reported emotional regulation and includes 10 items to assess means of coping with emotions via regulating them through reappraisal or suppression. Items range from 1 (strongly disagree) to 7 (strongly agree). Six of the items are summed to create the reappraisal total score, with total scores ranging from 6 to 42. Higher scores indicate greater emotional reappraisal.

    Time frame: Baseline (screening)

  12. Primary Endpoint Emotion Regulation Questionnaire (ERQ) Reappraisal Subscale

    ERQ measures self-reported emotional regulation and includes 10 items to assess means of coping with emotions via regulating them through reappraisal or suppression. Items range from 1 (strongly disagree) to 7 (strongly agree). Six of the items are summed to create the reappraisal total score, with total scores ranging from 6 to 42. Higher scores indicate greater emotional reappraisal.

    Time frame: Primary Endpoint (Visit 16, approximately 2 months later)

  13. Baseline Emotion Regulation Questionnaire (ERQ) Suppression Subscale

    ERQ measures self-reported emotional regulation and includes 10 items to assess means of coping with emotions via regulating them through reappraisal or suppression. Items range from 1 (strongly disagree) to 7 (strongly agree). Four of the items are summed to create the suppression total score, with total scores ranging from 4 to 28. Higher scores indicate greater emotional suppression.

    Time frame: Baseline (screening)

  14. Primary Endpoint Emotion Regulation Questionnaire (ERQ) Suppression Subscale

    ERQ measures self-reported emotional regulation and includes 10 items to assess means of coping with emotions via regulating them through reappraisal or suppression. Items range from 1 (strongly disagree) to 7 (strongly agree). Four of the items are summed to create the suppression total score, with total scores ranging from 4 to 28. Higher scores indicate greater emotional suppression.

    Time frame: Primary Endpoint (Visit 16, approximately 2 months later)

  15. Baseline Patient PTSD Checklist-5 (PCL-5)

    The PTSD Checklist-5 (PCL-5) is a 20-item self-reported questionnaire that follows DSM-5 criteria to assess PTSD presence and severity. Item scores range from 0 (not at all) to 4 (extremely). A total symptom severity score is determined by summing all items (range 0 to 80). A higher score indicates greater PTSD symptom severity.

    Time frame: Baseline (screening)

  16. Primary Endpoint Patient PTSD Checklist-5 (PCL-5)

    The PTSD Checklist-5 (PCL-5) is a 20-item self-reported questionnaire that follows DSM-5 criteria to assess PTSD presence and severity. Item scores range from 0 (not at all) to 4 (extremely). A total symptom severity score is determined by summing all items (range 0 to 80). A higher score indicates greater PTSD symptom severity.

    Time frame: Primary Endpoint (Visit 16, approximately 2 months later)

  17. Baseline Partner-rated PTSD Checklist-5 (PCL-5)

    The PTSD Checklist-5 (PCL-5) is a 20-item self-reported questionnaire that follows DSM-5 criteria to assess PTSD presence and severity. Item scores range from 0 (not at all) to 4 (extremely). A total symptom severity score is determined by summing all items (range 0 to 80). A higher score indicates greater PTSD symptom severity.

    Time frame: Baseline (screening)

  18. Primary Endpoint Partner-rated PTSD Checklist-5 (PCL-5)

    The PTSD Checklist-5 (PCL-5) is a 20-item self-reported questionnaire that follows DSM-5 criteria to assess PTSD presence and severity. Item scores range from 0 (not at all) to 4 (extremely). A total symptom severity score is determined by summing all items (range 0 to 80). A higher score indicates greater PTSD symptom severity.

    Time frame: Primary Endpoint (Visit 16, approximately 2 months later)

07

Results

Posted Jul 19, 2021

Participant flow

Participant flow — Overall Study
MilestonePatient MDMA and CBCTPartner MDMA and CBCT
Started66
Completed66
Not completed00

Outcome measures

PrimaryPrimary Endpoint Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a CAPS-5 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Primary Endpoint Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Primary Endpoint Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score16.3 ± 13.71
PrimaryChange From Baseline to Primary Endpoint CAPS-5 Total Severity Score

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a CAPS-5 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Change From Baseline to Primary Endpoint CAPS-5 Total Severity Score
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Change From Baseline to Primary Endpoint CAPS-5 Total Severity Score-25.7 ± 13.89
SecondaryBaseline Pittsburgh Sleep Quality Index (PSQI)

Self-reported questionnaire that assesses sleep quality and disturbances. The index looks at subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The component scores yield a total score which ranges 0-21 with a higher score indicating worse sleep quality.

Time frame:
Baseline (screening)
Reported as:
Mean · score on a scale
Baseline Pittsburgh Sleep Quality Index (PSQI)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Baseline Pittsburgh Sleep Quality Index (PSQI)14.24 ± 3.54
SecondaryPrimary Endpoint Pittsburgh Sleep Quality Index (PSQI)

Self-reported questionnaire that assesses sleep quality and disturbances. The index looks at subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The component scores yield a total score which ranges 0-21 with a higher score indicating worse sleep quality.

Time frame:
Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Primary Endpoint Pittsburgh Sleep Quality Index (PSQI)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Primary Endpoint Pittsburgh Sleep Quality Index (PSQI)10.37 ± 4.49
SecondaryBaseline Patient Beck Depression Inventory-II (BDI-II)

BDI-II is a 21-item self reported instrument used to measure severity of depressive symptoms. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.

Time frame:
Baseline (screening)
Reported as:
Mean · score on a scale
Baseline Patient Beck Depression Inventory-II (BDI-II)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Baseline Patient Beck Depression Inventory-II (BDI-II)32.91 ± 8.75
SecondaryPrimary Endpoint Patient Beck Depression Inventory-II (BDI-II)

BDI-II is a 21-item self reported instrument used to measure severity of depressive symptoms. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.

Time frame:
Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Primary Endpoint Patient Beck Depression Inventory-II (BDI-II)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Primary Endpoint Patient Beck Depression Inventory-II (BDI-II)12.75 ± 16.88
SecondaryBaseline Patient Couples Satisfaction Index (CSI)

The Couples Satisfaction Index (CSI) is a self-reported 32-item scale measuring one's satisfaction in a relationship. Questions discuss overall happiness in relationship, extent of agreement/ disagreement between partners, and feelings towards relationships and are scored on a likert scale from 0 to 5, with higher scores indicating higher satisfaction in the relationship. Scores range from 0 to 160.

Time frame:
Baseline (screening)
Reported as:
Mean · score on a scale
Baseline Patient Couples Satisfaction Index (CSI)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Baseline Patient Couples Satisfaction Index (CSI)105.37 ± 13.39
SecondaryPrimary Endpoint Patient Couples Satisfaction Index (CSI)

The Couples Satisfaction Index (CSI) is a self-reported 32-item scale measuring one's satisfaction in a relationship. Questions discuss overall happiness in relationship, extent of agreement/ disagreement between partners, and feelings towards relationships and are scored on a likert scale from 0 to 5, with higher scores indicating higher satisfaction in the relationship. Scores range from 0 to 160.

Time frame:
Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Primary Endpoint Patient Couples Satisfaction Index (CSI)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Primary Endpoint Patient Couples Satisfaction Index (CSI)127.00 ± 34.34
SecondaryBaseline Partner Couples Satisfaction Index (CSI)

The Couples Satisfaction Index (CSI) is a self-reported 32-item scale measuring one's satisfaction in a relationship. Questions discuss overall happiness in relationship, extent of agreement/ disagreement between partners, and feelings towards relationships and are scored on a likert scale from 0 to 5, with higher scores indicating higher satisfaction in the relationship. Scores range from 0 to 160.

Time frame:
Baseline (screening)
Reported as:
Mean · score on a scale
Baseline Partner Couples Satisfaction Index (CSI)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Baseline Partner Couples Satisfaction Index (CSI)98.1 ± 50.81
SecondaryPrimary Endpoint Partner Couples Satisfaction Index (CSI)

The Couples Satisfaction Index (CSI) is a self-reported 32-item scale measuring one's satisfaction in a relationship. Questions discuss overall happiness in relationship, extent of agreement/ disagreement between partners, and feelings towards relationships and are scored on a likert scale from 0 to 5, with higher scores indicating higher satisfaction in the relationship. Scores range from 0 to 160.

Time frame:
Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Primary Endpoint Partner Couples Satisfaction Index (CSI)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Primary Endpoint Partner Couples Satisfaction Index (CSI)125.34 ± 30.59
SecondaryBaseline Trauma and Attachment Beliefs Scale (TABS)

TABS is a 84-item self-report scale, which measures responses on a 1 to 6 scale (1 = "Disagree Strongly, 6 = Agree Strongly) the degree to which respondents believe the statements correspond with their own beliefs. The measures of these beliefs relate to self-safety, other-safety, self-trust, other-trust, self-esteem, other-esteem, self-intimacy, other-intimacy, self-control, and other control. A TABS total score is calculated by summing all of the items (range 84 to 504). Higher scores indicate greater disruption.

Time frame:
Baseline (screening)
Reported as:
Mean · score on a scale
Baseline Trauma and Attachment Beliefs Scale (TABS)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Baseline Trauma and Attachment Beliefs Scale (TABS)289.78 ± 44.30
SecondaryPrimary Endpoint Trauma and Attachment Beliefs Scale (TABS)

TABS is a 84-item self-report scale, which measures responses on a 1 to 6 scale (1 = "Disagree Strongly, 6 = Agree Strongly) the degree to which respondents believe the statements correspond with their own beliefs. The measures of these beliefs relate to self-safety, other-safety, self-trust, other-trust, self-esteem, other-esteem, self-intimacy, other-intimacy, self-control, and other control. A TABS total score is calculated by summing all of the items (range 84 to 504). Higher scores indicate greater disruption.

Time frame:
Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Primary Endpoint Trauma and Attachment Beliefs Scale (TABS)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Primary Endpoint Trauma and Attachment Beliefs Scale (TABS)232.7 ± 69.07
SecondaryBaseline Emotion Regulation Questionnaire (ERQ) Reappraisal Subscale

ERQ measures self-reported emotional regulation and includes 10 items to assess means of coping with emotions via regulating them through reappraisal or suppression. Items range from 1 (strongly disagree) to 7 (strongly agree). Six of the items are summed to create the reappraisal total score, with total scores ranging from 6 to 42. Higher scores indicate greater emotional reappraisal.

Time frame:
Baseline (screening)
Reported as:
Mean · score on a scale
Baseline Emotion Regulation Questionnaire (ERQ) Reappraisal Subscale
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Baseline Emotion Regulation Questionnaire (ERQ) Reappraisal Subscale21.77 ± 7.92
SecondaryPrimary Endpoint Emotion Regulation Questionnaire (ERQ) Reappraisal Subscale

ERQ measures self-reported emotional regulation and includes 10 items to assess means of coping with emotions via regulating them through reappraisal or suppression. Items range from 1 (strongly disagree) to 7 (strongly agree). Six of the items are summed to create the reappraisal total score, with total scores ranging from 6 to 42. Higher scores indicate greater emotional reappraisal.

Time frame:
Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Primary Endpoint Emotion Regulation Questionnaire (ERQ) Reappraisal Subscale
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Primary Endpoint Emotion Regulation Questionnaire (ERQ) Reappraisal Subscale28.34 ± 2.30
SecondaryBaseline Emotion Regulation Questionnaire (ERQ) Suppression Subscale

ERQ measures self-reported emotional regulation and includes 10 items to assess means of coping with emotions via regulating them through reappraisal or suppression. Items range from 1 (strongly disagree) to 7 (strongly agree). Four of the items are summed to create the suppression total score, with total scores ranging from 4 to 28. Higher scores indicate greater emotional suppression.

Time frame:
Baseline (screening)
Reported as:
Mean · score on a scale
Baseline Emotion Regulation Questionnaire (ERQ) Suppression Subscale
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Baseline Emotion Regulation Questionnaire (ERQ) Suppression Subscale18.96 ± 6.28
SecondaryPrimary Endpoint Emotion Regulation Questionnaire (ERQ) Suppression Subscale

ERQ measures self-reported emotional regulation and includes 10 items to assess means of coping with emotions via regulating them through reappraisal or suppression. Items range from 1 (strongly disagree) to 7 (strongly agree). Four of the items are summed to create the suppression total score, with total scores ranging from 4 to 28. Higher scores indicate greater emotional suppression.

Time frame:
Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Primary Endpoint Emotion Regulation Questionnaire (ERQ) Suppression Subscale
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Primary Endpoint Emotion Regulation Questionnaire (ERQ) Suppression Subscale13.63 ± 5.41
SecondaryBaseline Patient PTSD Checklist-5 (PCL-5)

The PTSD Checklist-5 (PCL-5) is a 20-item self-reported questionnaire that follows DSM-5 criteria to assess PTSD presence and severity. Item scores range from 0 (not at all) to 4 (extremely). A total symptom severity score is determined by summing all items (range 0 to 80). A higher score indicates greater PTSD symptom severity.

Time frame:
Baseline (screening)
Reported as:
Mean · score on a scale
Baseline Patient PTSD Checklist-5 (PCL-5)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Baseline Patient PTSD Checklist-5 (PCL-5)62.64 ± 6.35
SecondaryPrimary Endpoint Patient PTSD Checklist-5 (PCL-5)

The PTSD Checklist-5 (PCL-5) is a 20-item self-reported questionnaire that follows DSM-5 criteria to assess PTSD presence and severity. Item scores range from 0 (not at all) to 4 (extremely). A total symptom severity score is determined by summing all items (range 0 to 80). A higher score indicates greater PTSD symptom severity.

Time frame:
Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Primary Endpoint Patient PTSD Checklist-5 (PCL-5)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Primary Endpoint Patient PTSD Checklist-5 (PCL-5)23.96 ± 19.08
SecondaryBaseline Partner-rated PTSD Checklist-5 (PCL-5)

The PTSD Checklist-5 (PCL-5) is a 20-item self-reported questionnaire that follows DSM-5 criteria to assess PTSD presence and severity. Item scores range from 0 (not at all) to 4 (extremely). A total symptom severity score is determined by summing all items (range 0 to 80). A higher score indicates greater PTSD symptom severity.

Time frame:
Baseline (screening)
Reported as:
Mean · score on a scale
Baseline Partner-rated PTSD Checklist-5 (PCL-5)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Baseline Partner-rated PTSD Checklist-5 (PCL-5)49.58 ± 8.52
SecondaryPrimary Endpoint Partner-rated PTSD Checklist-5 (PCL-5)

The PTSD Checklist-5 (PCL-5) is a 20-item self-reported questionnaire that follows DSM-5 criteria to assess PTSD presence and severity. Item scores range from 0 (not at all) to 4 (extremely). A total symptom severity score is determined by summing all items (range 0 to 80). A higher score indicates greater PTSD symptom severity.

Time frame:
Primary Endpoint (Visit 16, approximately 2 months later)
Reported as:
Mean · score on a scale
Primary Endpoint Partner-rated PTSD Checklist-5 (PCL-5)
score on a scaleMDMA (75 mg or 100 mg) + CBCT
Primary Endpoint Partner-rated PTSD Checklist-5 (PCL-5)21.54 ± 19.67

Adverse events

Collected over Adverse events were collected from enrollment to study completion (a period of approximately 6 months) and at 6-month follow-up (1 year after enrollment).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PTSD Patients Open-label CBCT and MDMA-assisted Therapy (up to 2 Months Post Last Experimental Dose)0/6 (0%)0/6 (0%)6/6 (100%)
CSO Patients Open-label CBCT and MDMA-assisted Therapy (up to 2 Months Post Last Experimental Dose)0/6 (0%)0/6 (0%)6/6 (100%)
PTSD Patients at 6-month Follow-up0/6 (0%)0/6 (0%)2/6 (33.3%)
CSO Patients at 6-month Follow-up0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPTSD Patients Open-label CBCT and MDMA-assisted Therapy (up to 2 Months Post Last Experimental Dose)CSO Patients Open-label CBCT and MDMA-assisted Therapy (up to 2 Months Post Last Experimental Dose)PTSD Patients at 6-month Follow-upCSO Patients at 6-month Follow-up
NauseaGastrointestinal disorders2/60/60/60/6
FatigueGeneral disorders2/60/60/60/6
Upper respiratory tract infectionInfections and infestations2/61/60/60/6
Decreased appetiteMetabolism and nutrition disorders2/60/60/60/6
TinnitusEar and labyrinth disorders1/60/60/60/6
Visual ImpairmentEye disorders0/61/60/60/6
HypothyroidismEndocrine disorders0/60/61/60/6
VomitingGastrointestinal disorders0/61/60/60/6
AstheniaGeneral disorders1/60/60/60/6
Acute sinusitisInfections and infestations0/60/61/60/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Patient MDMA and CBCTPartner MDMA and CBCTTotal
Mean47.1 ± 12.5446.5 ± 11.1746.8 ± 11.33
Sex: Female, Male
Sex: Female, Male(Participants)Patient MDMA and CBCTPartner MDMA and CBCTTotal
Female246
Male426
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patient MDMA and CBCTPartner MDMA and CBCTTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6612
More than one race000
Unknown or Not Reported000
Baseline Global CAPS-5 Total Severity Score
Baseline Global CAPS-5 Total Severity Score(units on a scale)Patient MDMA and CBCTPartner MDMA and CBCTTotal
Mean42.0 ± 5.76—42.0 ± 5.76
08

Study locations

1 site
  • Offices of Michael Mithoefer MD
    Mount Pleasant, South Carolina 29464, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We plan to share outcome measure data upon request

Supporting information: Study protocol, Statistical analysis plan

Time frame: After study data lock

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Dec 2017, 17 months.

Results were first posted in Jul 2021, 3 years 7 months after primary completion. A results delay was requested in Jun 2019.

Of 17 phase 1/2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2016
First posted
Aug 23, 2016
StartActual
Jul 3, 2016
Primary completionActual
Dec 16, 2017
CompletionActual
May 29, 2018
Results delay requested
Jun 26, 2019
Results first posted
Jul 19, 2021
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02876172
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Aug 23, 2016
Start date
Jul 3, 2016
Primary completion
Dec 16, 2017
Completion
May 29, 2018
Results posted
Jul 19, 2021
Last update
Jun 4, 2025

Study contacts

Michael C Mithoefer, MD
principal investigator · Private Practice

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion